Amphastar Pharmaceuticals, Inc. Q3 2025 Earnings Recap

Amphastar Pharmaceuticals reported solid third-quarter results, achieving net revenues of $191.8 million and a 14% year-over-year sales increase for BAQSIMI, while significantly expanding its proprietary pipeline.

Key Takeaways

• Q3 net revenues rose to $191.8 million, driven by strong performances in BAQSIMI and Primatene MIST.
• BAQSIMI sales hit a record high of $53.6 million, an increase of 14% year-over-year, aided by enhanced sales execution.
• The company secured U.S. and Canadian rights for three early-stage peptide candidates, broadening its pipeline with a market potential exceeding $60 billion.
• FDA approval of iron sucrose injection (AMP-002) was achieved, contributing $2.4 million in sales during the quarter.
• Amphastar is on track for multiple product launches in 2026 and 2027, positioning itself strategically in competitive therapeutic markets.